AstraZeneca to Acquire EsoBiotec for Up to $1 Billion
Drugmaker AstraZeneca has announced that it will acquire biotechnology firm EsoBiotec for up to $1 billion on a cash and debt-free basis.
About EsoBiotec’s Technology
EsoBiotec’s Engineered NanoBody Lentiviral (ENaBL) platform is a breakthrough technology that enables the direct genetic modification of immune cells within the body. This allows for transformative cell therapy treatments in just minutes, as opposed to the current process, which can take weeks.
AstraZeneca will acquire all outstanding equity of EsoBiotec for a cash and debt-free basis, with an initial payment of $425 million on deal closing, and up to $575 million in contingent consideration based on development and regulatory milestones.
The transaction is expected to close in the second quarter of 2025 and does not impact AstraZeneca’s financial guidance for 2025.
Conclusion
The acquisition of EsoBiotec’s technology is a strategic move by AstraZeneca to expand its presence in the field of cellular therapy. The ENaBL platform has the potential to revolutionize the way we approach cell therapy, and AstraZeneca’s commitment to developing this technology will bring significant benefits to patients worldwide.
FAQs
Q: What is the cost of the acquisition?
A: The acquisition is valued at up to $1 billion on a cash and debt-free basis.
Q: What is the timeline for the acquisition?
A: The transaction is expected to close in the second quarter of 2025.
Q: How will this acquisition impact AstraZeneca’s financial guidance?
A: The acquisition does not impact AstraZeneca’s financial guidance for 2025.
Q: What is the significance of the ENaBL platform?
A: The ENaBL platform has the potential to revolutionize the way we approach cell therapy, allowing for transformative treatments in just minutes instead of weeks.
